Healthcare
Puma Biotechnology, Inc.(PBYI)
Live Price
Offline$7.56
+4.56% today
1Y Change
+116.62%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $380.00M
- Revenue Growth
- -0.9%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Puma Biotechnology, Inc. (PBYI) is a Healthcare stock with a market cap of $380.00M and listed on NASDAQ. The stock last traded around $7.56 and up 116.6% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -0.9%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue -0.9%, EPS 0.0%, free cash flow +7.4% with operating margin 16.3% and ROIC 20.4%. Valuation is more restrained than many high-expectation growth names at P/E 12.1 and price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PBYI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.9% vs +7.6% peer median
Operating Margin
Below sector median
+16.3% vs +19.4% peer median
P/E
Below sector median
12.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.9% and EPS is at 0.0%, with operating margin around 16.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.8% | -1.9% | +1.9% |
2026 Feb 26, 2026 | +20.8% | -25.0% | -18.0% | -17.5% |
2025 Nov 6, 2025 | +133.3% | +22.2% | +1.0% | +8.2% |
Benchmark Edge
PBYI vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PBYI
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PBYI Max Drawdown
-25.78%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PBYI and SPY.
Company Overview
Puma Biotechnology, Inc.
NASDAQ Global Select
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
- Leadership
- Alan H. Auerbach
- IPO Date
- Apr 24, 2012
- Employees
- 172
- Street Address
- 10880 Wilshire Boulevard
- Mailing
- Los Angeles, CA, 90024
- Region
- Los Angeles, CA, US
- Reporting Currency
- USD
- Investor Line
- 424 248 6500
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 12.1
- EV/EBITDA
- 6.4
- Price/Sales
- 1.7
- Price/Book
- 2.9
Growth
- Revenue
- -0.9%
- EPS
- 0.0%
- Free Cash Flow
- +7.4%
Profitability
- Gross Margin
- 74.5%
- Operating Margin
- 16.3%
- Net Margin
- 13.6%
- ROE
- 27.8%
- ROIC
- 20.4%
Balance Sheet
- Debt/Equity
- 0.22
- Current Ratio
- 2.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.